Molecular typing is predicated on molecular genetic screening and isn't still routinely obtainable. Molecular subtypes and immunohistochemical surrogate markers on the tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 might be useful, https://ellenq641nvd9.wiki-jp.com/user